New drug combo aims to shrink rectal tumors before surgery
NCT ID NCT06647680
Summary
This study is testing whether giving a combination of chemotherapy and an immunotherapy drug before surgery can help shrink rectal tumors and improve outcomes. The trial will enroll 35 adults with locally advanced rectal cancer who haven't spread to other organs. Participants receive three cycles of treatment over nine weeks before undergoing surgery, followed by three years of monitoring to track results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The affiliated hospital of Qingdao university
RECRUITINGQingdao, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.